We would love to hear your thoughts about our site and services, please take our survey here.
All the low life out today
2nd January 2019--Presidential Decree on Matanda Received
http://www.victoriaoilandgas.com/investors/news/presidential-decree-matanda-received
24th December 2018-Renewal of Long-Term Gas Supply Contract with ENEO
http://www.victoriaoilandgas.com/investors/news/renewal-long-term-gas-supply-contract-eneo
2nd January 2019--Presidential Decree on Matanda Received
http://www.victoriaoilandgas.com/investors/news/presidential-decree-matanda-received
24th December 2018-Renewal of Long-Term Gas Supply Contract with ENEO
http://www.victoriaoilandgas.com/investors/news/renewal-long-term-gas-supply-contract-eneo
16 January 2019
Allergy Therapeutics plc
Trading Update & Notice of Results
Sales continue to grow strongly
Strong cash position sustained by good performance
16 January 2019 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunology vaccines, today provides a trading update for the six months ended 31 December 2018 ahead of its Half Year Results to be announced on 6 March 2019.
Financials
The Group is trading in line with Board expectations. Reported revenues for the six months ended 31 December 2018 are expected to be £46.7m (2017: £42.2m) representing 10.6% growth on both a reported and constant currency basis. In terms of geography, the main contributors to this strong sales growth are Germany, Austria, Switzerland and Netherlands. Spain has continued to grow well despite the withdrawal of all bacterial products across the market. In terms of product mix, this growth is being driven primarily by the Group's ultra-short course, aluminium-free treatments (Pollinex and Pollinex Quattro) as well as Acarovac and Venomil. The Group continues to gain market share in Germany1 and again achieved number one position in this market for the month of October 2018 (the Group's busiest month of the year) for the second year running2.
The cash balance at the end of December 2018 was £31.6m (31 December 2017: £25.8m).
Regulatory
The Group continues to make good progress with the peanut allergy vaccine outsourced manufacturing scale up and the Acarovac Phase I trial for dust mite allergies. The first in-human trials for the Polyvac peanut product are expected to start in 2019, and data from the Acarovac Phase I trial is expected in H1 2019. As announced in December 2018, the top line results of the PQ Birch Phase III trial will be announced in Q1 2019. Meetings with the FDA and the German regulator, the Paul-Ehrlich-Institut (PEI), in relation to the PQ Grass trials are scheduled for Q1 2019.
Manuel Llobet, CEO at Allergy Therapeutics, stated: "This is another period of revenue growth and continued gain in market share for Allergy Therapeutics, in line with our mid and long-term strategy. The Group is also making good progress across its clinical pipeline, with a number of key developments anticipated for the first half of this year. We see momentum in the business and look forward to updating the market at our interim results."
1Insight Health Data November 2018
2 Insight Health Data October 2018
http://www.lse.co.uk/share-regulatory-news.asp?shareprice=AGY&ArticleCode=gl64pbpq&ArticleHeadline=Trading_Update__Notice_of_Results
2nd January 2019--Presidential Decree on Matanda Received
http://www.victoriaoilandgas.com/investors/news/presidential-decree-matanda-received
24th December 2018-Renewal of Long-Term Gas Supply Contract with ENEO
http://www.victoriaoilandgas.com/investors/news/renewal-long-term-gas-supply-contract-eneo
So, you are being an arse to try and disrupt the VOG BB to try and buy in at a lower price! lol, that was your DEB tactic!
and god knows how many other usernames, I'd concentrate on DEB rather than posting stupid comments on companies you have sold-up on at a loss to then buy in here at 8p!
So many aliases on LSE but I remember sage and markettimer (so probably bigsmoke too) were keen on FLYB!
2nd January 2019--Presidential Decree on Matanda Received
http://www.victoriaoilandgas.com/investors/news/presidential-decree-matanda-received
24th December 2018-Renewal of Long-Term Gas Supply Contract with ENEO
http://www.victoriaoilandgas.com/investors/news/renewal-long-term-gas-supply-contract-eneo
oldtimer and 3c!
Ignore the idiots
"As it happens I do hold debs"
I know you hold DEB, you told everyone here that you sold VOG and bought into the 'positive' recovery story of DEB and then you got banned from LSE for......probably a list of reasons!
Keep playing with your marbles before you lose them! :-)
Whether you knew it or not, you invested in a high risk AIM company and not...……………………….can't think of a sector that isn't without risk after the last ten years or so!
Most on this BB posted that VOG would be gone or at least require major funding by end of 2018 and sold into the story, they have bought back in now!
http://www.victoriaoilandgas.com/investors/news/presidential-decree-matanda-received
http://www.victoriaoilandgas.com/investors/news/renewal-long-term-gas-supply-contract-eneo
Anyway, got sewerage pipe to rod through now, lovely!
For goodness sake grow-up, you are not stuck in a share!
Look at the bigger picture and the recent positive news flow regarding VOG/GDC!
http://www.lse.co.uk/member-info.asp?nick=NOVECKINGOOD&page=6
yet another wind-up merchant!
But at least it's taken all the idiots from ADVFN to here, including Tom!
looks like bigsmoke and the gang never told you they were all buying back in!
No wonder you are all bitter and twisted! :-)
Even bigsmoke and his merry man are buying back in after selling-up!
"As I predicted, starting to see gradual retrace with no further news on immediate horizon."- Have you taken over from oldtimer...……….
is another wind-up merchant, just ignore the...…………...hmmmmm, can't say idiot!
and the rest of the wind-up merchants-filtered!